Prevention of @entity1489 and @entity272 during XXXX therapy in renal transplant recipients: a double-blind, placebo-controlled study.

@entity1 @entity14028 @entity1489 @entity957 @entity189 @entity165 @entity412 @entity272 @entity1491
PURPOSE: The purpose of this study was to investigate the effect of @entity14028 on the development of @entity272 , and on @entity957 and @entity1491 in a group of renal transplant recipients. @entity1 AND METHODS: Forty-four renal transplant recipients with more than 10 @entity272 on the hands and forearms were enrolled onto a randomized, double-blind, placebo-controlled trial to test the possible @entity1489 -preventing effect of a 6-month treatment with @entity14028 30 mg/d. RESULTS: No deterioration in renal function occurred in any of the 38 assessable @entity1 treated. During the 6-month treatment period, two of 19 @entity1 (11%) in the @entity14028 group reported a total of two new @entity957 , compared with nine of 19 @entity1 (47%) in the placebo group who developed a @entity189 (chi 2 = 6.27, P = .01). The relative decrease in the number of @entity272 in the @entity14028 group was 13.4%, as compared with a relative increase in the placebo group of 28.2% (difference, 41.6%; 95% confidence interval, 11.5 to 71.7). Most @entity1 treated with @entity14028 had mild mucocutaneous side effects, but these were easily manageable. Some @entity1 experienced mild hair loss. With the exception of three @entity1 , no increase in serum @entity165 or @entity412 above pretreatment levels was observed, and liver function remained unchanged in all @entity1 . CONCLUSION: @entity14028 30 mg/d over 6 months had significantly more effect than placebo in the prevention of @entity957 and reduced the occurrence of @entity272 in a group of renal transplant recipients with severe lesions. This effect was most pronounced in @entity1 with a history of @entity957 and @entity1491 .
